| Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised … JL Lennox, E DeJesus, A Lazzarin, RB Pollard, JVR Madruga, DS Berger, ... The Lancet 374 (9692), 796-806, 2009 | 741 | 2009 |
| Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial JV Madruga, P Cahn, B Grinsztejn, R Haubrich, J Lalezari, A Mills, ... The Lancet 370 (9581), 29-38, 2007 | 623 | 2007 |
| Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority … P Cahn, AL Pozniak, H Mingrone, A Shuldyakov, C Brites, ... The Lancet 382 (9893), 700-708, 2013 | 619 | 2013 |
| Cabotegravir for HIV prevention in cisgender men and transgender women RJ Landovitz, D Donnell, ME Clement, B Hanscom, L Cottle, L Coelho, ... New England Journal of Medicine 385 (7), 595-608, 2021 | 584 | 2021 |
| Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised … JV Madruga, D Berger, M McMurchie, F Suter, D Banhegyi, ... The Lancet 370 (9581), 49-58, 2007 | 448 | 2007 |
| Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active … A Mills, JR Arribas, J Andrade-Villanueva, G DiPerri, J Van Lunzen, ... The Lancet Infectious Diseases 16 (1), 43-52, 2016 | 376 | 2016 |
| Raltegravir versus efavirenz regimens in treatment-naive HIV-1–infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses JL Lennox, E DeJesus, DS Berger, A Lazzarin, RB Pollard, JVR Madruga, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 55 (1), 39-48, 2010 | 297 | 2010 |
| Mpox in people with advanced HIV infection: a global case series O Mitjà, A Alemany, M Marks, JIL Mora, JC Rodríguez-Aldama, MST Silva, ... The Lancet 401 (10380), 939-949, 2023 | 281 | 2023 |
| Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials C Katlama, R Haubrich, J Lalezari, A Lazzarin, JV Madruga, JM Molina, ... Aids 23 (17), 2289-2300, 2009 | 233 | 2009 |
| Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial JJ Eron, JK Rockstroh, J Reynes, J Andrade-Villanueva, ... The Lancet infectious diseases 11 (12), 907-915, 2011 | 226 | 2011 |
| The safety and efficacy of tenofovir df in combination with lamivudine and efavirenz through 6 years in antiretroviral-naïve HIV-1—infected patients I Cassetti, JVR Madruga, JMAH Suleiman, A Etzel, L Zhong, AK Cheng, ... HIV clinical trials 8 (3), 164-172, 2007 | 223 | 2007 |
| Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study B Grinsztejn, B Hoagland, RI Moreira, EG Kallas, JV Madruga, S Goulart, ... The lancet HIV 5 (3), e136-e145, 2018 | 195 | 2018 |
| Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial SMART Study Group* Annals of internal medicine 149 (5), 289-299, 2008 | 166 | 2008 |
| High pre‐exposure prophylaxis uptake and early adherence among men who have sex with men and transgender women at risk for HIV Infection: the PrEP Brasil demonstration project B Hoagland, RI Moreira, RB De Boni, EG Kallas, JV Madruga, ... Journal of the International AIDS Society 20 (1), 21472, 2017 | 144 | 2017 |
| Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial B Grinsztejn, N De Castro, V Arnold, VG Veloso, M Morgado, JH Pilotto, ... The Lancet infectious diseases 14 (6), 459-467, 2014 | 134 | 2014 |
| Awareness and willingness to use pre-exposure prophylaxis (PrEP) among men who have sex with men and transgender women in Brazil B Hoagland, RB De Boni, RI Moreira, JV Madruga, EG Kallas, SP Goulart, ... AIDS and Behavior 21, 1278-1287, 2017 | 114 | 2017 |
| Barriers to access to care reported by women living with HIV across 27 countries M Johnson, A Samarina, H Xi, J Valdez Ramalho Madruga, L Hocqueloux, ... AIDS care 27 (10), 1220-1230, 2015 | 107 | 2015 |
| The Safety and Efficacy of Switching Stavudine to Tenofovir DF in Combination with Lamivudine and Efavirenz in HIV-1—Infected Patients: Three-Year Follow–up After Switching … JVR Madruga, I Cassetti, JMAH Suleiman, A Etzel, L Zhong, CB Holmes, ... HIV clinical trials 8 (6), 381-390, 2007 | 88 | 2007 |
| Primary antiretroviral drug resistance among HIV type 1-infected individuals in Brazil E Sprinz, EM Netto, MPJS Lima, JJD Furtado, M da Eira, R Zajdenverg, ... AIDS research and human retroviruses 25 (9), 861-867, 2009 | 69 | 2009 |
| DUET-1: Week-48 results of a phase III randomized double-blind trial to evaluate the efficacy and safety of TMC125 vs placebo in 612 treatment-experienced HIV-1-infected patients R Haubrich, P Cahn, B Grinsztejn, J Lalezari, J Madruga, A Mills 15th Conference on Retroviruses and Opportunistic Infections, 3-6, 2008 | 64 | 2008 |
